Non-Alcoholic Steatohepataitis (NASH) Pipeline Analysis 2017 - Research and Markets
February 28 2017 - 5:29AM
Business Wire
Research and Markets has announced the addition of the
"Non-Alcoholic Steatohepataitis (NASH) Pipeline Analysis" report to
their offering.
Non-alcoholic steatohepataitis (NASH) Pipeline Analysis gives
comprehensive insights on the various drugs being developed for the
treatment of NASH. The report covers all the drugs that are in
various phases of development (Discovery, Preclinical &
Clinical). The pipeline focuses on novel pharmacologic drugs &
regenerative medicines covering small molecules, antibodies, stem
cell therapies, recombinant proteins and RNA-based therapeutics,
but excludes symptom relief drugs, generic combinations and
supplemental drugs. The report also covers some of the hot targets
in research for NASH treatments and NASH related biomarkers.
This report enables Pharmaceutical/Biotech companies, Academic
institutes, Individual researchers, Investors, Medical technology
companies, Service providers and other associated stake holders to
identify and analyze the available licensing/collaborative
commercial opportunities in the Non-alcoholic steatohepataitis
(NASH) drugs market. The report also provides strategic insights on
some of the molecules that are yet to be launched in the next few
years.
Key Topics Covered:
1 REPORT DESCRIPTION
2 INTRODUCTION
2.1 Causes & Symptoms
2.2 Diagnosis
2.3 Unmet needs
2.4 Current therapies
3 HOT TARGETS, MECHANISMS & THERAPIES
3.1 Novel Disease mechanisms & therapies
3.2 Leading targets of NASH
3.3 Novel targets of NASH
3.4 NASH biomarkers
3.5 Genes Involved in NASH
4 MARKET DATA
4.1 Forecasting model
4.2 Market dynamics
4.3 Market sizing
4.4 NASH Deals
4.5 Funding Scenario
5 PIPELINE ANALYSIS
5.1 Development stage
5.2 Leading players
5.3 Therapeutic segmentation
5.4 Target analysis
5.5 Clinical update on phase 3 molecules
5.6 Innovative approaches
6 SMALL MOLECULES
6.1 Pipeline
6.2 Competitive Analysis
7 LARGE MOLECULE
7.1 Competitive Analysis
8 RNA-BASED THERAPY
8.1 Pipeline
8.2 Competitive Analysis
9 RECOMBINANT PROTEINS
9.1 Pipeline
9.2 Competitive Analysis
10 ANTIBODIES
10.1 Pipeline
10.2 Competitive Analysis
11 LARGE MOLECULES (UNSPECIFIED)
11.1 Pipeline
12 OTHER MOLECULES
12.1 Pipeline
13 NASH DRUG ANALYSIS BASED ON MECHANISMS
14 MAJOR PLAYERS
14.1 Company Profiles
14.2 Overview
14.3 Pipeline
14.4 Deals
15 REFERENCES
For more information about this report visit
http://www.researchandmarkets.com/research/xg4s9j/nonalcoholic
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170228005884/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T. Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Related Topics: Liver and Kidney Disorders
Drugs